{"id":2879,"date":"2020-07-31T00:00:00","date_gmt":"2020-07-31T04:00:00","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/journal-articles\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\/"},"modified":"2023-06-14T19:49:25","modified_gmt":"2023-06-14T23:49:25","slug":"a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\/","title":{"rendered":"A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin"},"content":{"rendered":"<p><strong>Background <\/strong>&#x2014; Bleomycin is commonly used to treat advanced testicular cancer and can be associated with severe pulmonary toxicity. The primary objective of the present study was to describe the use of pulmonary function tests (pfts) and chest imaging before, during, and after treatment with bleomycin.<\/p>\n<p><strong>Methods <\/strong>&#x2014; To identify all incident cases of testicular cancer treated with bleomycin-based chemotherapy in the Canadian province of Ontario during 2005&#x2013;2010, the Ontario Cancer Registry was linked with chemotherapy treat&#xad;ment records. Health administrative databases were used to describe use of pfts, chest imaging, and physician visits for respiratory complaints.<\/p>\n<p><strong>Results <\/strong>&#x2014; Of 394 patients treated with orchiectomy and chemotherapy who received at least 1 dose of bleomycin, 93% had complete chemotherapy records available. In the 4 weeks before, during, and within 2 years after finishing bleomycin-based chemotherapy, pfts were performed in 17%, 17%, and 29% of patients respectively. Chest imaging was performed in 68%, 62%, and 98% of patients in the same time periods. In the 2 years after bleomycin-based chemotherapy, 23% of treated patients had a physician visit for respiratory symptoms. That rate was substantially higher for men with greater exposure to bleomycin: 40% (24 of 60) for 10&#x2013;12 doses bleomycin compared with 21% (53 of 250) for 7&#x2013;9 doses and with 14% (8 of 58) for 1&#x2013;6 doses (p = 0.002).<\/p>\n<p><strong>Conclusions <\/strong>&#x2014; Quality improvement initiatives are needed to increase baseline rates of chest imaging within 4 weeks of starting chemotherapy for testicular cancer; to understand why such a high proportion of men have chest imaging during bleomycin-based chemotherapy; and to mitigate the excess pulmonary toxicity seen with increasing expos&#xad;ure to bleomycin.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Background &#x2014; Bleomycin is commonly used to treat advanced testicular cancer and can be associated with severe pulmonary toxicity. The primary objective of the present study was to describe the use of pulmonary function tests (pfts) and chest imaging before, during, and after treatment with bleomycin. Methods &#x2014; To identify all incident cases of testicular [&hellip;]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[],"migration-helper-qa-sample-set":[],"class_list":["post-2879","journal_article","type-journal_article","status-publish","hentry"],"acf":{"citation":"Raphael MJ, Lougheed MD, Wei X, Karim S, Robinson AG, Bedard PL, Booth CM. <em>Curr Oncol<\/em>. 2020; 27(6):291-98. Epub 2020 Jul 31.","source_url":"https:\/\/www.current-oncology.com\/index.php\/oncology\/article\/view\/6389","ices_scientist":[1294],"site":[6736],"research_program":[6741],"news_release":[],"journal_article":[],"atlas":[],"research_report":[],"infographic":[],"video":[],"downloads":null,"links":null,"sitecore_item_id":"6939E389-A282-4219-8761-8EBD3F432613","sitecore_item_name":"A-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular","sitecore_field_values":"{\n  \"Title\": \"A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin\",\n  \"Short title\": \"A population-based study of\",\n  \"Summary\": \"The objective this study was to describe the use of pulmonary function tests (pfts) and chest imaging before, during, and after treatment with bleomycin.\",\n  \"Citation\": \"<p>Raphael MJ, Lougheed MD, Wei X, Karim S, Robinson AG, Bedard PL, Booth CM. <em>Curr Oncol<\/em>. 2020; 27(6):291-98. Epub 2020 Jul 31. DOI: <a href=\"https:\/\/doi.org\/10.3747\/co.27.6389\" title=\"Opens external link\">https:\/\/doi.org\/10.3747\/co.27.6389<\/a><\/p>\",\n  \"Abstract\": \"<p><strong>Background <\/strong>&mdash; Bleomycin is commonly used to treat advanced testicular cancer and can be associated with severe pulmonary toxicity. The primary objective of the present study was to describe the use of pulmonary function tests (pfts) and chest imaging before, during, and after treatment with bleomycin.<\/p>n<p><strong>Methods <\/strong>&mdash; To identify all incident cases of testicular cancer treated with bleomycin-based chemotherapy in the Canadian province of Ontario during 2005&ndash;2010, the Ontario Cancer Registry was linked with chemotherapy treat\u00adment records. Health administrative databases were used to describe use of pfts, chest imaging, and physician visits for respiratory complaints.<\/p>n<p><strong>Results <\/strong>&mdash; Of 394 patients treated with orchiectomy and chemotherapy who received at least 1 dose of bleomycin, 93% had complete chemotherapy records available. In the 4 weeks before, during, and within 2 years after finishing bleomycin-based chemotherapy, pfts were performed in 17%, 17%, and 29% of patients respectively. Chest imaging was performed in 68%, 62%, and 98% of patients in the same time periods. In the 2 years after bleomycin-based chemotherapy, 23% of treated patients had a physician visit for respiratory symptoms. That rate was substantially higher for men with greater exposure to bleomycin: 40% (24 of 60) for 10&ndash;12 doses bleomycin compared with 21% (53 of 250) for 7&ndash;9 doses and with 14% (8 of 58) for 1&ndash;6 doses (p = 0.002).<\/p>n<p><strong>Conclusions <\/strong>&mdash; Quality improvement initiatives are needed to increase baseline rates of chest imaging within 4 weeks of starting chemotherapy for testicular cancer; to understand why such a high proportion of men have chest imaging during bleomycin-based chemotherapy; and to mitigate the excess pulmonary toxicity seen with increasing expos\u00adure to bleomycin.<\/p>n<p><a href=\"https:\/\/www.current-oncology.com\/index.php\/oncology\/article\/view\/6389\" title=\"Opens external link\">View full text<\/a><\/p>\",\n  \"Research Programs\": \"{85DE96A6-4C96-40C7-8E6D-7597A0EB5F80}\",\n  \"ICES Locations\": \"{5A12C65D-3CDA-413E-BC94-C1D778156CE6}\",\n  \"ICES Scientists\": \"{A5C099AF-7BCD-437A-AD7E-75FC8F887742}|{BFD4A032-E01A-43E2-BD46-A5E210C9706E}\",\n  \"Posted Date\": \"20200731T000000\",\n  \"Show on Publications Landing Page\": \"1\"\n}","previous_url":"https:\/\/www.ices.on.ca\/Publications\/Journal-Articles\/2020\/July\/A-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICES | A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin<\/title>\n<meta name=\"description\" content=\"Background &#x2014; Bleomycin is commonly used to treat advanced testicular cancer and can be associated with severe pulmonary toxicity. The primary\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin\" \/>\n<meta property=\"og:description\" content=\"Background &#x2014; Bleomycin is commonly used to treat advanced testicular cancer and can be associated with severe pulmonary toxicity. The primary\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T23:49:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\\\/\",\"name\":\"ICES | A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2020-07-31T04:00:00+00:00\",\"dateModified\":\"2023-06-14T23:49:25+00:00\",\"description\":\"Background &#x2014; Bleomycin is commonly used to treat advanced testicular cancer and can be associated with severe pulmonary toxicity. The primary\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin","description":"Background &#x2014; Bleomycin is commonly used to treat advanced testicular cancer and can be associated with severe pulmonary toxicity. The primary","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin","og_description":"Background &#x2014; Bleomycin is commonly used to treat advanced testicular cancer and can be associated with severe pulmonary toxicity. The primary","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2023-06-14T23:49:25+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\/","name":"ICES | A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2020-07-31T04:00:00+00:00","dateModified":"2023-06-14T23:49:25+00:00","description":"Background &#x2014; Bleomycin is commonly used to treat advanced testicular cancer and can be associated with severe pulmonary toxicity. The primary","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/a-population-based-study-of-pulmonary-monitoring-and-toxicity-for-patients-with-testicular-cancer-treated-with-bleomycin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/2879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6741"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6736"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1294"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=2879"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=2879"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=2879"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=2879"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=2879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}